Santa Clara, CA. November 06, 2012 - Leveraging their unique drug discovery and translational research platforms, Crown Bioscience and Horizon Discovery today announced the availability of X-MAN cell lines in vivo as well as in vitro, to facilitate the development of novel oncology targets and early-stage drug discovery programs within the pharmaceutical industry…

Santa Clara, CA (PRWEB) January 11, 2012 - Crown Bioscience, Inc., a leading global drug discovery company, and Jiangsu Hengrui Medicine Co., Ltd. ("Hengrui"), a major Chinese pharmaceutical company, today announced that CrownBio Taicang Biologics Division, a wholly owned subsidiary of Crown Bioscience, Inc., and Hengrui have entered into a strategic partnership for the discovery and commercialization of a novel therapeutic monoclonal antibody ("mAb") for the Chinese and global market.

Santa Clara, California (PRWEB) August 11, 2011 -- Japan's pharmaceutical and biotech drug development programs gain easy access and technical support of CrownBio's unique translational oncology assets HuPrime® and HuBase™ with Japan's premier technical sales organization On Target.

SANTA CLARA, Calif., May 4, 2011 /PRNewswire/ -- Crown Bioscience, Inc., a leading company in innovative oncology R&D partnership and services, today announced the closing of a US$28.8 million Series C financing. The proceeds will be used for expanding services in integrated cancer drug discovery and translational oncology, as well as to fund new initiatives in other therapeutic areas.  

Crown Bioscience, Inc. announces their partnership with Allostem Therapeutics providing discovery and pre-clinical translational oncology services for Allostem’s MEK inhibitor program CIP-137401 is the clinical candidate from a novel MEK inhibitor scaffold with Best-In-Class potential.

Santa Clara, CA (PRWEB) April 1, 2011 -- Crown Bioscience, Inc. announces their partnership with Allostem Therapeutics (Farmington, CT) providing discovery and pre-clinical Cancer Biology services for Allostem’s MEK inhibitor program. CIP-137401 is the clinical candidate from a novel MEK inhibitor scaffold with Best-In-Class potential.

Crown Bioscience, Inc. announces their partnership with Jasco Pharmaceuticals (Woburn, MA) providing discovery and pre-clinical Cancer Biology services for Jasco’s lead program.

Santa Clara, CA (PRWEB) December 7, 2010 -- Crown Bioscience, Inc. announces their partnership with Jasco Pharmaceuticals (Woburn, MA) providing discovery and pre-clinical Cancer Biology services for Jasco’s lead program. Jasco Pharmaceuticals will leverage Crown Bio’s unique models, powerful molecular profiling, and data analysis capabilities providing Jasco Pharma’s high speed medicinal chemistry approach with a synergistic biological complement accelerating the development of Jasco Pharmaceuticals’ novel small molecule Pim inhibitors.